Pensionfund Dsm Netherlands Cut Its Hcp (HCP) Stake; Fate Therapeutics (FATE) Had 8 Analysts Last Week

November 25, 2017 - By Migdalia James

Pensionfund Dsm Netherlands decreased Hcp Inc (HCP) stake by 14.47% reported in 2017Q2 SEC filing. Pensionfund Dsm Netherlands sold 16,000 shares as Hcp Inc (HCP)’s stock rose 2.09%. The Pensionfund Dsm Netherlands holds 94,593 shares with $3.02M value, down from 110,593 last quarter. Hcp Inc now has $12.69B valuation. The stock increased 0.64% or $0.17 on November 24, reaching $26.88. About 880,694 shares traded. HCP, Inc. (NYSE:HCP) has risen 8.01% since November 25, 2016 and is uptrending. It has underperformed by 8.69% the S&P500.

Among 8 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics had 9 analyst reports since October 6, 2015 according to SRatingsIntel. H.C. Wainwright reinitiated the shares of FATE in report on Thursday, October 12 with “Buy” rating. The firm has “Buy” rating by BMO Capital Markets given on Wednesday, November 1. The rating was initiated by Roth Capital on Thursday, September 22 with “Buy”. Raymond James initiated it with “Outperform” rating and $8 target in Tuesday, October 6 report. BMO Capital Markets initiated it with “Outperform” rating and $4 target in Tuesday, April 12 report. The firm has “Outperform” rating by Wedbush given on Tuesday, November 8. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. The stock of Fate Therapeutics Inc (NASDAQ:FATE) has “Buy” rating given on Friday, September 8 by Leerink Swann. The stock has “Buy” rating by TH Capital on Thursday, September 22. See Fate Therapeutics Inc (NASDAQ:FATE) latest ratings:

01/11/2017 Broker: BMO Capital Markets Rating: Buy New Target: $7.0 Maintain
12/10/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $7 Reinitiate
08/09/2017 Broker: Leerink Swann Rating: Buy New Target: $7.0 Initiate

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $175.08 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

The stock increased 1.20% or $0.05 on November 24, reaching $4.2. About 39,696 shares traded. Fate Therapeutics Inc (NASDAQ:FATE) has risen 166.12% since November 25, 2016 and is uptrending. It has outperformed by 149.42% the S&P500.

Investors sentiment decreased to 1.43 in 2017 Q2. Its down 4.97, from 6.4 in 2017Q1. It turned negative, as 11 investors sold Fate Therapeutics Inc shares while 12 reduced holdings. 19 funds opened positions while 14 raised stakes. 25.76 million shares or 48.07% less from 49.60 million shares in 2017Q1 were reported. 23,500 are held by Dimensional Fund Advsr Ltd Partnership. Tiaa Cref Investment Mngmt Ltd Liability Com reported 115,275 shares. Tfs Cap Limited Liability Corp holds 34,107 shares or 0.04% of its portfolio. New York State Common Retirement Fund accumulated 40,500 shares. California-based Ecor1 Ltd Co has invested 1.46% in Fate Therapeutics Inc (NASDAQ:FATE). Schwab Charles Inv Mngmt Incorporated holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 66,000 shares. Barclays Public Limited Company accumulated 0% or 11,668 shares. Invesco has 0% invested in Fate Therapeutics Inc (NASDAQ:FATE). Citigroup Inc owns 0% invested in Fate Therapeutics Inc (NASDAQ:FATE) for 97 shares. Bridgeway Capital Mgmt accumulated 250,000 shares. Northern Trust Corporation reported 368,208 shares or 0% of all its holdings. Goldman Sachs Gru, a New York-based fund reported 111,775 shares. First Manhattan reported 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Rhumbline Advisers accumulated 40,967 shares or 0% of the stock. Kingdon Cap Mngmt Ltd Llc stated it has 1.15 million shares.

Analysts await HCP, Inc. (NYSE:HCP) to report earnings on February, 12. They expect $0.47 earnings per share, down 20.34% or $0.12 from last year’s $0.59 per share. HCP’s profit will be $221.89 million for 14.30 P/E if the $0.47 EPS becomes a reality. After $0.48 actual earnings per share reported by HCP, Inc. for the previous quarter, Wall Street now forecasts -2.08% negative EPS growth.

Investors sentiment increased to 1.23 in 2017 Q2. Its up 0.14, from 1.09 in 2017Q1. It increased, as 35 investors sold HCP shares while 170 reduced holdings. 63 funds opened positions while 190 raised stakes. 411.39 million shares or 1.65% more from 404.71 million shares in 2017Q1 were reported. Quebec – Canada-based Caisse De Depot Et Placement Du Quebec has invested 0.01% in HCP, Inc. (NYSE:HCP). Security Capital And Management Incorporated reported 4.38% of its portfolio in HCP, Inc. (NYSE:HCP). Wendell David Associate stated it has 0.12% of its portfolio in HCP, Inc. (NYSE:HCP). 28,292 were accumulated by Rand Wealth Lc. Amp Capital Invsts Limited has invested 0.08% in HCP, Inc. (NYSE:HCP). Hodges Management owns 0.02% invested in HCP, Inc. (NYSE:HCP) for 9,975 shares. Geode Capital Management Limited Liability has invested 0.07% in HCP, Inc. (NYSE:HCP). Bancshares stated it has 0.01% in HCP, Inc. (NYSE:HCP). New Mexico Educational Retirement Board holds 0.17% or 107,800 shares in its portfolio. State Street Corp, a Massachusetts-based fund reported 27.36 million shares. Trillium Asset Mngmt Lc reported 529,463 shares. Atria Invests Llc stated it has 12,447 shares or 0.02% of all its holdings. Jefferies Gp Llc, a New York-based fund reported 153,656 shares. 53,400 were accumulated by Teachers Retirement System Of The State Of Kentucky. Point72 Asia (Hong Kong) Limited invested 0% in HCP, Inc. (NYSE:HCP).

Among 19 analysts covering HCP (NYSE:HCP), 2 have Buy rating, 1 Sell and 16 Hold. Therefore 11% are positive. HCP had 63 analyst reports since September 8, 2015 according to SRatingsIntel. The stock of HCP, Inc. (NYSE:HCP) has “Neutral” rating given on Wednesday, August 24 by Citigroup. The stock has “Hold” rating by Jefferies on Monday, May 15. The firm earned “Hold” rating on Monday, September 4 by BMO Capital Markets. The firm has “Neutral” rating by Mizuho given on Wednesday, November 2. The rating was maintained by BMO Capital Markets with “Hold” on Tuesday, August 1. KeyBanc Capital Markets maintained the shares of HCP in report on Tuesday, November 21 with “Hold” rating. The firm has “Equal Weight” rating by Barclays Capital given on Thursday, January 5. The rating was maintained by RBC Capital Markets on Monday, August 7 with “Hold”. The firm earned “Underweight” rating on Thursday, March 10 by Barclays Capital. The stock of HCP, Inc. (NYSE:HCP) earned “Hold” rating by Jefferies on Thursday, July 13.